title: Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
abstract: Motor neuron diseases are neurological disorders characterized primarily by the degeneration of spinal motor neurons, skeletal muscle atrophy, and debilitating and often fatal motor dysfunction. Spinal muscular atrophy (SMA) is an autosomal-recessive motor neuron disease of high incidence and severity and the most common genetic cause of infant mortality. SMA is caused by homozygous mutations in the survival motor neuron 1 (SMN1) gene and retention of at least one copy of the hypomorphic gene paralog SMN2. Early studies established a loss-of-function disease mechanism involving ubiquitous SMN deficiency and suggested SMN upregulation as a possible therapeutic approach. In recent years, greater knowledge of the central role of SMN in RNA processing combined with deep characterization of animal models of SMA has significantly advanced our understanding of the cellular and molecular basis of the disease. SMA is emerging as an RNA disease not limited to motor neurons, but one that involves dysfunction of motor circuits that comprise multiple neuronal subpopulations and possibly other cell types. Advances in SMA research have also led to the development of several potential therapeutics shown to be effective in animal models of SMA that are now in clinical trials. These agents offer unprecedented promise for the treatment of this still incurable neurodegenerative disease.
authors.affiliation: Center for Motor Neuron Biology and Disease and Department of Pathology and Cell Biology, Columbia University, New York, New York 10032.
authors.forename: Sarah
authors.initials: S
authors.lastname: Tisdale
authors.affiliation: Center for Motor Neuron Biology and Disease and Department of Pathology and Cell Biology, Columbia University, New York, New York 10032 lp2284@cumc.columbia.edu.
authors.forename: Livio
authors.initials: L
authors.lastname: Pellizzoni
mesh_terms: D015316:Genetic Therapy; D006801:Humans; D009134:Muscular Atrophy, Spinal / Q000235:genetics* / Q000628:therapy*; D009154:Mutation / Q000235:genetics*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D017411:Ribonucleoproteins, Small Nuclear; D055533:Survival of Motor Neuron 1 Protein / Q000235:genetics*; D055540:Survival of Motor Neuron 2 Protein / Q000235:genetics*
chemical_list: D016376:Oligonucleotides, Antisense; D017411:Ribonucleoproteins, Small Nuclear; D055533:Survival of Motor Neuron 1 Protein; D055540:Survival of Motor Neuron 2 Protein